[Form 4] ADMA BIOLOGICS, INC. Insider Trading Activity
Rhea-AI Filing Summary
Adam S. Grossman, President & CEO and director of ADMA BIOLOGICS (ADMA), reported multiple transactions on 09/15/2025 under a previously disclosed Rule 10b5-1 plan. He exercised a stock option to acquire 15,000 shares at an exercise price of $5.40 and sold a total of 21,000 shares (15,000 and 6,000) at $16.13. After these transactions he directly owned 2,025,850 shares and indirectly controlled an additional 1,724,383 shares through Areth, LLC and Hariden, LLC. The option exercised was originally granted on 02/26/2024 and vests through 02/26/2028. The reporting person also holds unvested RSUs totaling 1,033,966 across grants from 2022–2025 that will settle into common stock upon vesting.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider used a pre-existing 10b5-1 plan to exercise options and reduce holdings via sales while keeping a large ownership stake.
The filing shows routine, pre-planned activity rather than opportunistic trading: a 15,000-share option exercise at $5.40 and sales of 21,000 shares at $16.13 executed under a 10b5-1 plan. The CEO retains substantial direct ownership (2,025,850 shares) plus indirect control of 1,724,383 shares, and holds material unvested RSUs and an option pool. For investors, this indicates continued alignment with company performance through significant retained equity while permitting limited monetization under a structured plan.
TL;DR: Transactions were executed under a disclosed 10b5-1 plan and include standard option vesting disclosures; governance appears compliant and transparent.
The Form 4 discloses the 10b5-1 plan date (12/05/2024) and provides detailed vesting schedules for RSUs and options, including the February 26, 2024 option grant and vesting through 2028. Ownership is reported clearly with direct and indirect holdings (Areth and Hariden LLCs) identified. The filing includes necessary explanatory footnotes and a dated signature, indicating procedural adherence to Section 16 reporting requirements.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 15,000 | $0.00 | -- |
| Exercise | Common Stock | 15,000 | $5.40 | $81K |
| Sale | Common Stock | 15,000 | $16.13 | $242K |
| Sale | Common Stock | 6,000 | $16.13 | $97K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer. The price reported in Column 4 is the price at which the shares were sold. Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 993,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth. These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden. The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
